Weidong Han
Chinese PLA General Hospital
CancerEndocrinologyOncologyAntigenMesenchymal stem cellImmunologyT cellChemotherapyImmunotherapyDecitabineWound healingStem cellChimeric antigen receptorCancer researchSignal transductionMedicineBiologyImmune systemCell biologyCancer cell
229Publications
50H-index
6,165Citations
Publications 221
Newest
#1Xiaoyan SongH-Index: 1
#2Xiaoya SunH-Index: 1
Last. Yiming Mu (Chinese PLA General Hospital)H-Index: 19
view all 6 authors...
This study was designed to assess whether the combination of the glucagon-like peptide-1 (GLP-1) analog exendin-4 (Ex4) and bone marrow-derived mesenchymal stem cell (BM-MSC) could enhance β-cell action in STZ-induced diabetic rats. Forty male SD rats were randomly assigned to five groups: the normal control group (Normal), diabetes group (DM), MSC-treated group (MSC), Ex4-treated group (Ex4) and MSC plus Ex4-treated group (MSC + Ex4). Body weight, blood glucose level, intraperitoneal glucose to...
Source
#1Xiaolei Li (Anhui Medical University)
#2Hanren Dai (Anhui Medical University)H-Index: 23
Last. Weidong Han (Chinese PLA General Hospital)H-Index: 50
view all 4 authors...
Source
#1Yang Liu (Chinese PLA General Hospital)H-Index: 17
#1Yang Liu (Chinese PLA General Hospital)H-Index: 3
Last. Weidong Han (Chinese PLA General Hospital)H-Index: 50
view all 13 authors...
Background Programmed death-1 (PD-1) blockade monotherapy induced durable remission in a subset of patients with relapsed/refractory classical Hodgkin lymphoma (cHL). We asked whether the anti-PD-1 agent, camrelizumab, combined with the DNA demethylating agent, decitabine, improves progression-free survival (PFS) in patients with relapsed/refractory cHL over camrelizumab alone. Methods This extended follow-up of an ongoing randomized phase II trial analyzed PFS among patients enrolled from Janua...
Source
#1Jianshu Wei (Chinese PLA General Hospital)H-Index: 5
#2Yelei Guo (Chinese PLA General Hospital)H-Index: 22
Last. Weidong Han (Chinese PLA General Hospital)H-Index: 50
view all 8 authors...
Chimeric antigen receptor (CAR) T-cell therapy has achieved significant success in the treatment of hematological malignancies. In recent years, fast-growing CAR T clinical trials have actively explored their potential application scenarios. According to the data from the clinicaltrials.gov website, China became the country with the most registered CAR T trials in September 2017. As of June 30, 2020, the number of registered CAR T trials in China has reached 357. In addition, as many as 150 othe...
4 CitationsSource
#1Xiang Li (Capital Medical University)
#1Xiang LiH-Index: 17
Last. Jing NieH-Index: 15
view all 9 authors...
Background CD4+ T cells play multiple roles in controlling tumor growth and increasing IFN-γ+ T-helper 1 cell population could promote cell-mediated anti-tumor immune response. We have previously showed that low-dose DNA demethylating agent decitabine therapy promotes CD3+ T-cell proliferation and cytotoxicity; however, direct regulation of purified CD4+ T cells and the underlying mechanisms remain unclear. Methods The effects of low-dose decitabine on sorted CD4+ T cells were detected both in v...
Source
#1Chunmeng Wang (Chinese PLA General Hospital)H-Index: 9
#2Yang Liu (Chinese PLA General Hospital)H-Index: 3
Last. Weidong Han (Chinese PLA General Hospital)H-Index: 50
view all 13 authors...
Purpose: Programmed death-1 (PD-1) blockade monotherapy is effective in relapsed/refractory classical Hodgkin lymphoma (cHL), but a subset of patients is recalcitrant to PD-1 inhibitors and only a minority of patients achieves durable remission. Effective treatment regimens for those with relapsed/progressive cHL after single-agent anti-PD-1 are urgently needed. Anti-PD-1 combination with DNA demethylating agent decitabine showed positive preliminary results in our test cohort patients who were ...
Source
#1Dongdong Ti (Chinese PLA General Hospital)H-Index: 16
#2Miaomiao Bai (Chinese PLA General Hospital)H-Index: 5
Last. Weidong Han (Chinese PLA General Hospital)H-Index: 50
view all 8 authors...
Impaired tumor-specific effector T cells contribute to tumor progression and unfavorable clinical outcomes. As a compensatory T cell-dependent cancer immunoediting strategy, adoptive T cell therapy (ACT) has achieved encouraging therapeutic results, and this strategy is now on the center stage of cancer treatment and research. ACT involves the ex vivo stimulation and expansion of tumor-infiltrating lymphocytes (TILs) with inherent tumor reactivity or T cells that have been genetically modified t...
1 CitationsSource
#1Yao WangH-Index: 24
#2Chuan TongH-Index: 19
Last. Weidong Han (Yahoo!)H-Index: 50
view all 16 authors...
Insufficient eradication capacity and dysfunction are common occurrences in T cells that characterize cancer immunotherapy failure. De novo DNA methylation promotes T cell exhaustion, whereas methylation inhibition enhances T cell rejuvenation in vivo. Decitabine, a DNA methyltransferase inhibitor approved for clinical use, may provide a means of modifying exhaustion-associated DNA methylation programmes. Herein, anti-tumour activities, cytokine production, and proliferation are enhanced in deci...
2 CitationsSource
#1Qingzhu Jia (Third Military Medical University)H-Index: 14
#2Diyuan Qin (Sichuan University)
Last. Bo Zhu (Third Military Medical University)H-Index: 34
view all 23 authors...
Rationale: The onset of cytokine release syndrome (CRS) and in vivo persistence of anti-CD19 chimeric antigen receptor T (CAR-T) cells after infusion correlate with clinical responsiveness. However, there are no known baseline biomarkers that can predict the prognosis of patients with B-lineage non-Hodgkin lymphoma (B-NHL). The aim of this study was to identify blood cell populations associated with beneficial outcomes in B-NHL patients administered CAR-T cell immunotherapies. Methods: We enumer...
Source
#1Miaomiao BaiH-Index: 5
#2Dongdong TiH-Index: 16
Last. Weidong HanH-Index: 50
view all 9 authors...
The human body is a complex structure of cells, which are exposed to many types of stress. Cells must utilize various mechanisms to protect their DNA from damage caused by metabolic and external sources to maintain genomic integrity and homeostasis and to prevent the development of cancer. DNA damage inevitably occurs regardless of physiological or abnormal conditions. In response to DNA damage, signaling pathways are activated to repair the damaged DNA or to induce cell apoptosis. During the pr...
Source